Akero Therapeutics, Inc. financial data

Symbol
AKRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
601 Gateway Boulevard, Suite 350, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.22K % -10.5%
Debt-to-equity 9.19 % +0.33%
Return On Equity -32.2 % -8.21%
Return On Assets -29.5 % -8.19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.6M shares
Common Stock, Shares, Outstanding 72.4M shares +29.8%
Entity Public Float 1.57B USD -37.7%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 67.1M shares +27.7%
Weighted Average Number of Shares Outstanding, Diluted 67.1M shares +27.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 247M USD +74.5%
General and Administrative Expense 37.9M USD +22.1%
Operating Income (Loss) -285M USD -65.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -252M USD -66.1%
Earnings Per Share, Basic -3.75 USD/shares -29.8%
Earnings Per Share, Diluted -3.75 USD/shares -29.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 340M USD +45.3%
Marketable Securities, Current 403M USD +27.6%
Cash, Cash Equivalents, and Short-term Investments 798M USD +40.1%
Assets, Current 770M USD +37.6%
Property, Plant and Equipment, Net 15K USD -25%
Operating Lease, Right-of-Use Asset 755K USD -25.1%
Other Assets, Noncurrent 108K USD -76.9%
Assets 826M USD +42.3%
Accounts Payable, Current 9.03M USD +28.3%
Employee-related Liabilities, Current 1.17M USD -9.65%
Liabilities, Current 39.8M USD +108%
Operating Lease, Liability, Noncurrent 529K USD -35.4%
Liabilities 75.8M USD +68.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 948K USD +251%
Retained Earnings (Accumulated Deficit) -826M USD -43.9%
Stockholders' Equity Attributable to Parent 750M USD +40.1%
Liabilities and Equity 826M USD +42.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -35.1M USD -42.7%
Net Cash Provided by (Used in) Financing Activities 367M USD +2322%
Net Cash Provided by (Used in) Investing Activities 57.8M USD +229%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 72.4M shares +29.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 340M USD +45.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 768K USD +175%
Deferred Tax Assets, Valuation Allowance 242M USD +36.5%
Deferred Tax Assets, Gross 249M USD +38.5%
Operating Lease, Liability 820K USD -24%
Depreciation 1K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -251M USD -65.9%
Lessee, Operating Lease, Liability, to be Paid 900K USD -26.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 351K USD +2.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 341K USD +3.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 80K USD -47.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 208K USD -40.7%
Deferred Tax Assets, Operating Loss Carryforwards 116M USD +31.2%
Unrecognized Tax Benefits 5.89M USD +73.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 208K USD -40.7%
Operating Lease, Payments 331K USD +3.12%
Additional Paid in Capital 1.5B USD +43.9%
Deferred Tax Assets, Net of Valuation Allowance 7.19M USD +168%
Share-based Payment Arrangement, Expense 29.7M USD +38.2%
Interest Expense 4.67M USD +50.6%